Related Videos
Video
Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients
Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.
Video
cHL and CLL SLL Panel Discussion and Conclusion
In this video, the panel takes audience questions and discusses cases of Classical Hodgkin Lymphoma, Chronic Lymphocutic Leukemia, and Small Lymphocytic Lymphoma.
Video
Ann LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.